2024
Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-dependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStay
2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2020
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting
2014
The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital
Gehrie EA, Tormey CA. The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital. Military Medicine 2014, 179: 1099-1105. PMID: 25269127, DOI: 10.7205/milmed-d-14-00045.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood BanksBlood Grouping and CrossmatchingBlood Loss, SurgicalBlood TransfusionClinical AuditClinical ProtocolsConnecticutEmergenciesErythrocyte TransfusionFactor VIIaFactor VIIIFibrinogenHematemesisHospitals, VeteransHumansLaboratories, HospitalMalePlasma ExchangePlatelet TransfusionPostoperative HemorrhageRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsConceptsFresh frozen plasmaRecombinant factor VIIaRed blood cellsVeterans Affairs hospitalTransfusion protocolFactor VIIaUnits of RBCsVeterans Affairs Connecticut Healthcare SystemUnits of FFPLarge trauma centersHospital-based blood banksETP patientsMassive transfusionTrauma centerFrozen plasmaSeparate patientsPatientsWest HavenBleeding emergenciesBlood bankBlood cellsYears' experienceHealthcare systemPlateletsHospital
2013
Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions
Unni N, Peddinghaus M, Tormey CA, Stack G. Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 2013, 54: 98-103. PMID: 23711236, DOI: 10.1111/trf.12251.Peer-Reviewed Original ResearchConceptsPercent of patientsTransfusion recordsNearby hospitalLocation of transfusionAntibody test resultsBlood group antibodiesHealth care facilitiesPrior transfusionsAntibody testingIncompatible transfusionsGroup antibodiesTransfusion activityTransfusionCare facilitiesPatientsState HospitalHemolytic reactionHospitalStudy designScreen testingAntibodiesCommon discrepancyStudy goalPercentRecords